{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T21:53:38Z","timestamp":1785621218190,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["456474\/2013-5"],"award-info":[{"award-number":["456474\/2013-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005993","name":"National Council for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.sapharm.2019.02.008","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T11:25:38Z","timestamp":1550921138000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The benefits of a public pharmacist service in chronic hepatitis C treatment: The real-life results of sofosbuvir-based therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Lenyta Oliveira","family":"Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Rodrigues","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fanior Andr\u00e9 da","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Aparecida","family":"Foppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Raijche Mattozo","family":"Rover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareni Rocha","family":"Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2019.02.008_bib1","series-title":"Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.sapharm.2019.02.008_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.sapharm.2019.02.008_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ajg.2014.66","article-title":"The rapid evolution of treatment strategies for hepatitis C","volume":"109","author":"Muir","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sapharm.2019.02.008_bib4","series-title":"Brasil; Minist\u00e9rio da Sa\u00fade; Departamento de DST, AIDS e Hepatites Virais. Boletim Epidemiol\u00f3gico - Hepatites Virais","year":"2018"},{"key":"10.1016\/j.sapharm.2019.02.008_bib5","series-title":"Brasil; Minist\u00e9rio da Sa\u00fade; Departamento de DST, AIDS e Hepatites Virais. Boletim Epidemiol\u00f3gico - Hepatites Virais","year":"2017"},{"key":"10.1016\/j.sapharm.2019.02.008_bib6","series-title":"Brasil. Minist\u00e9rio da Da\u00fade. Departamento de DST, AIDS e Hepatites Virais. Manual t\u00e9cnico para o diagn\u00f3stico das hepatites virais","year":"2015"},{"key":"10.1016\/j.sapharm.2019.02.008_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.13095","article-title":"Managing drug\u2013drug interactions with new direct-acting antiviral agents in chronic hepatitis C","volume":"83","author":"Pons","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2019.02.008_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/phar.1700","article-title":"Therapeutic advances in HCV genotype 1 infection: insights from the society of infectious diseases pharmacists","volume":"36","author":"Deming","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.sapharm.2019.02.008_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2146\/ajhp150704","article-title":"Genotype 1 hepatitis C virus and the pharmacist's role in treatment","volume":"73","author":"Sebhatu","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sapharm.2019.02.008_bib10","first-page":"709","article-title":"The expanding role of the pharmacist in the management of hepatitis C infection","volume":"17","author":"Spooner","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.sapharm.2019.02.008_bib11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/phar.1512","article-title":"Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection","volume":"34","author":"Mohammad","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.sapharm.2019.02.008_bib12","first-page":"815","article-title":"Advancing patient care through specialty pharmacy services in an academic health system","volume":"23","author":"Bagwell","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.sapharm.2019.02.008_bib13","first-page":"364","article-title":"Outcomes of pharmacy-led hepatitis C direct-acting antiviral utilization management at veterans affairs medical center","volume":"23","author":"Yang","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.sapharm.2019.02.008_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.12988","article-title":"Improving pharmacotherapy outcomes in patients with Hepatitis C virus infection treated with direct-acting antivirals","volume":"71","author":"Chamorro-de-Vega","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.sapharm.2019.02.008_bib15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.japh.2016.06.013","article-title":"Pharmacist engagement within a Hepatitis C ambulatory care clinic in the era of a treatment revolution","volume":"56","author":"Gauthier","year":"2016","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.sapharm.2019.02.008_bib16","series-title":"An\u00e1lise de conte\u00fado","volume":"70","author":"Bardin","year":"2006"},{"key":"10.1016\/j.sapharm.2019.02.008_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","article-title":"Treating viral hepatitis C: efficacy, side effects and complications","volume":"55","author":"Manns","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.sapharm.2019.02.008_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.sapharm.2019.02.008_bib19","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s10620-006-9579-1","article-title":"Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?","volume":"52","author":"Khokhar","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.sapharm.2019.02.008_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1525-1497.2005.0161.x","article-title":"Barriers to the treatment of hepatitis C: patient, provider, and system factors","volume":"20","author":"Morrill","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.sapharm.2019.02.008_bib21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/hep.26246","article-title":"A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care","volume":"57","author":"McGowan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.sapharm.2019.02.008_bib22","article-title":"The impact of illustrated side effect information on understanding and sustained retention of antiretroviral side effect knowledge","volume":"18","author":"Browne","year":"2018","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.sapharm.2019.02.008_bib23","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1377\/hlthaff.2014.1193","article-title":"Broad hepatitis C treatment scenarios return substantial health gains, but capacity is a concern","volume":"34","author":"Van Nuys","year":"2015","journal-title":"Health Aff"},{"key":"10.1016\/j.sapharm.2019.02.008_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S2214-109X(15)00156-4","article-title":"Disparity in market prices for hepatitis C virus direct-acting drugs","volume":"3","author":"Andrieux-Meyer","year":"2015","journal-title":"Lancet Glob Health"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741118308349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741118308349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:17:51Z","timestamp":1761556671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741118308349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1551741118308349"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2019.02.008","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The benefits of a public pharmacist service in chronic hepatitis C treatment: The real-life results of sofosbuvir-based therapy","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2019.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}